Group Introduction
[Its Dual-Listed Companies] Joincare Pharmaceutical Group (Stock Code: 600380 GDR Code：JCARE) Livzon Pharmaceutical Group (Stock Code: 000513 Hong Kong Stock Code: 01513)
Lizhu Pharmaceutical Group Co., Ltd.
Company Profile
Livzon Pharmaceutical Group Co., Ltd. was founded in January 1985, with a registered capital of 935 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production, and sales. It currently has more than 8,000 employees. ， A+H share listed company. 20 20 year degree The company's operating income 105.2 billion yuan, net profit 21.31 billion yuan, R&D investment of 989 million yuan, and tax payment of 1.279 billion yuan.
The company has made continuous breakthroughs in the fields of chemical drugs, biological drugs, in vitro diagnostic reagents, raw materials, and traditional Chinese medicine, with products distributed in the fields of digestion, cardiovascular and cerebrovascular, reproductive endocrinology, and mental/nervous systems.
Industry Chain Layout
Chemical Drug Field: Following the success of Lizhu Dele, from the national Class 1.1 new drug, enteric-coated rabeprazole tablets, to injectable rabeprazole sodium, after more than ten years of research and development, another blockbuster series of products in the digestive field has been developed.
Microsphere Field: Livzon is one of the earliest companies in China to have listed microsphere products. Currently, several exploratory new drug R&D projects are underway, and it is the only company in China to apply for a 3-month sustained-release microsphere.
Biopharmaceutical Field: It has built a typical demonstration base for antibody drug industrialization in Guangdong Province, with a technology platform integrating antibody humanization, cell line screening, large-scale cell culture, purification, preparation, analysis and testing, and quality control.
Diagnostic Reagent Field: It possesses multiple technology platforms such as enzyme immunoassay, colloidal gold, microbiology, molecular detection, and multiplex immunoassay, and its market share in respiratory infections, infectious diseases, and drug concentration monitoring is in a leading position in China.
Raw Material Field: Many products rank first in global/national market share, and have established long-term strategic partnerships with world-renowned companies such as Pfizer, TEVA, Baxter, and Zoetis, and have been rated as a high-quality supplier in the international market.
Traditional Chinese Medicine Field: It has its own GAP planting bases in Hunyuan, Shanxi and Longxi, Gansu, and the marketed products Shenqi Fuzheng Injection and Antiviral Granules are Livzon's exclusive products. Currently, several R&D projects are also in the clinical stage.
Future Development
Livzon's development is inseparable from the continuous influx of outstanding talents and sustained high-growth R&D investment. The company has built a comprehensive network of scientists, continuously recruiting top talents globally. The R&D team has hundreds of doctoral and high-end R&D personnel. In the future, Livzon will continue to focus on the life health field, continuously improve the quality of life for patients, continue to shoulder social responsibilities and missions, actively participate in public welfare undertakings, and accelerate the company's pace towards globalization.
Official Website Link: http://www.livzon.com.cn
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.